McKesson (NYSE:MCK) EVP Francisco Fraga Sells 600 Shares of Company Stock

McKesson Corporation (NYSE:MCK) EVP Francisco Fraga sold 600 shares of the firm’s stock in a transaction that occurred on Wednesday, November 4th. The shares were sold at an average price of $1,050.00, for a total value of $630,000.00. Following the completion of the sale, the executive vice president directly owned 5,064 shares of the company’s stock, valued at $5,317,200. This trade represents a 10.59% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Francisco Fraga also recently made the following trade(s):

• On Thursday, October 15th, Francisco Fraga sold 800 shares of McKesson stock. The shares were sold at an average price of $995.80, for a total value of $796,640.00.

McKesson Stock Up 0.6%

Shares of NYSE:MCK opened at $1,075.38 on Friday. McKesson Corporation has a twelve month low of $723.68 and a twelve month high of $1,121.50. The stock’s 50 day moving average is $934.72 and its 200-day moving average is $866.92. The firm has a market capitalization of $125.38 billion, a price-to-earnings ratio of 27.65, a PEG ratio of 2.13 and a beta of 0.27.

McKesson (NYSE:MCK) last issued its earnings results on Wednesday, November 4th. The company reported $11.68 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $10.72 by $0.96. The company had revenue of $110.96 billion for the quarter, compared to analysts’ expectations of $109.90 billion. McKesson had a negative return on equity of 235.48% and a net margin of 1.12%. McKesson’s quarterly revenue was up 7.5% compared to the same quarter last year. During the same period last year, the business earned $9.86 EPS. Equities research analysts anticipate that McKesson Corporation will post 44.71 earnings per share for the current fiscal year.

McKesson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, January 4th. Investors of record on Tuesday, December 1st will be given a $0.94 dividend. The ex-dividend date of this dividend is Tuesday, December 1st. This represents a $3.76 annualized dividend and a yield of 0.3%. McKesson’s dividend payout ratio (DPR) is presently 9.67%.

Institutional Investors Weigh In On McKesson

Institutional investors have recently added to or reduced their stakes in the company. King Luther Capital Management Corp raised its stake in McKesson by 1.6% during the third quarter. King Luther Capital Management Corp now owns 49,889 shares of the company’s stock valued at $42,596,000 after buying an additional 793 shares during the last quarter. Bingham Private Wealth LLC boosted its holdings in McKesson by 4.2% in the third quarter. Bingham Private Wealth LLC now owns 577 shares of the company’s stock worth $493,000 after acquiring an additional 23 shares in the last quarter. Maryland State Retirement & Pension System boosted its holdings in McKesson by 7.9% in the third quarter. Maryland State Retirement & Pension System now owns 7,190 shares of the company’s stock worth $6,139,000 after acquiring an additional 527 shares in the last quarter. Ritholtz Wealth Management grew its stake in shares of McKesson by 6.3% in the third quarter. Ritholtz Wealth Management now owns 14,918 shares of the company’s stock worth $12,737,000 after acquiring an additional 887 shares during the last quarter. Finally, UNIVEST FINANCIAL Corp grew its stake in shares of McKesson by 4.3% in the third quarter. UNIVEST FINANCIAL Corp now owns 675 shares of the company’s stock worth $576,000 after acquiring an additional 28 shares during the last quarter. 85.07% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several analysts have recently commented on MCK shares. Morgan Stanley set a $977.00 price objective on McKesson in a research note on Tuesday, October 6th. TD Cowen lifted their target price on McKesson from $1,006.00 to $1,200.00 and gave the company a “buy” rating in a research report on Thursday. Robert W. Baird set a $1,015.00 price target on McKesson in a report on Thursday, August 6th. Weiss Ratings upgraded McKesson from a “buy (b-)” rating to a “buy (b)” rating in a report on Friday, September 4th. Finally, Bank of America increased their price target on McKesson from $950.00 to $1,050.00 in a research report on Thursday, August 6th. Fifteen investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat, McKesson presently has a consensus rating of “Moderate Buy” and a consensus target price of $1,023.24.

Key Stories Impacting McKesson

Here are the key news stories impacting McKesson this week:

• Positive Sentiment: For fiscal Q2 2027, McKesson reported adjusted EPS of $11.68 versus analyst estimates near $10.70, while revenue of about $111 billion also topped expectations and grew roughly 7.5% year over year. MCK Q2 Earnings Beat Estimates on Specialty Growth, Outlook Raised
• Positive Sentiment: Management raised fiscal 2027 adjusted EPS guidance to $45.60–$46.40, citing specialty-drug demand, higher prescription volumes, operating improvements and GLP-1 momentum. The company also completed its $2.25 billion Precision Medicine Group acquisition, expanding its healthcare services footprint. Earnings Call Highlights: Raised Guidance, GLP-1 Momentum
• Positive Sentiment: Several firms raised targets, including TD Cowen, Leerink Partners and Evercore ISI to $1,200; Deutsche Bank raised its target to $1,120. RBC also praised McKesson’s execution, and a Seeking Alpha analysis described normalized earnings as supporting an attractive valuation. TD Cowen Raises Price Target
• Neutral Sentiment: EVP Francisco Fraga sold 600 shares under a pre-arranged trading plan to cover tax withholding on vested equity awards; he retained 5,064 shares, making the transaction less indicative of a change in business outlook. SEC Filing
• Negative Sentiment: RBC’s “sector perform” rating came with a $965 target—below the recent share price—suggesting limited upside in that firm’s view despite its target increase. RBC on McKesson’s Execution

McKesson Company Profile

McKesson Corporation is a healthcare services and information technology company that distributes pharmaceuticals and medical products to pharmacies, hospitals, health systems, physicians and other healthcare providers. The company also provides technology, data and business solutions designed to support prescription management, pharmacy operations and patient care.

McKesson’s principal activities include pharmaceutical distribution, medical-surgical supply distribution, specialty pharmaceutical services and oncology care support.